Coherus BioSciences plans to price its biosimilar of Amgen's Neulasta, an infection-fighting treatment, at $4,175 per unit, according to Reuters. This is a 33 percent discount off the price of the brand name drug.
Udenyca, the biosimilar approved by the FDA last week, is used to decrease the incidence of infection by helping the body make white blood cells after receiving cancer medications. Coherus will launch the drug Jan. 3.
Neulasta has a list price of $6,231 per unit, driving Amgen's sales of the drug to $4.53 billion in 2017.
This is the second biosimilar of Neulasta launched: Mylan's biosimilar, Fulphila, was approved earlier this year.